Loading clinical trials...

RECRUITINGPHASE1

Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Phase I Trial of Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

NCT06080061•Stanford University

Summary

The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy
•ECOG performance status of 0-2
•Age \> 18 years old
•Ability to understand and the willingness to personally sign the written IRB approved informed consent document
•Estimated life expectancy of 12 weeks or longer

Exclusion Criteria

•Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist
•Age \< 18 years old
•Tumor directly invading the major pulmonary arteries, aorta, heart or proximal bronchial tree
•Diagnosis of interstitial pulmonary fibrosis
•Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields

Locations (1)

Stanford University

Palo Alto, California, United States

Key Dates

Start Date

October 25, 2023

Primary Completion Date

November 1, 2026

Completion Date

December 1, 2026

Last Updated

July 15, 2025

Enrollment

ESTIMATED participants

Conditions

Lung Cancer

Interventions

Hypofractionated accelerated radiation therapy

RADIATION

Contacts

Alyssa Yauger

CONTACT

650-498-5271 ayauger@stanford.edu

Mimi Le-Budka

CONTACT

650-498-1933 mlebudka@stanford.edu

Magnetic Resonance Imaging of the Lung: Oncological Applications

NCT07486219

Lung Cancer (NSCLC)

View study

RECRUITINGPHASE2

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

NCT07336732

Non-Small-Cell Lung Cancer

View study

RECRUITINGPHASE1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 15, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Inclusion Criteria

Exclusion Criteria

Magnetic Resonance Imaging of the Lung: Oncological Applications

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer